Floatz logo

FLORTAUCIPIR

Progressive Posterior Cortical Dysfunction (PPCD)

Tammie L. S. Benzinger, MD, PhDSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Progressive Posterior Cortical Dysfunction (PPCD) cohort.

Asset / SponsorPhaseRating
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
Phase 1CC
FLORTAUCIPIR
Mayo Clinic
D
FLORTAUCIPIR
Mayo Clinic
D
ER-176
Mayo Clinic
D

Same molecule, other indications

FLORTAUCIPIR is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
frontotemporal dementiaDormant
BBB
Indicative ·
73 / 100
View asset →
primary progressive aphasiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →